Skip to main content

Confidence Intervals: Additional Commentary

  • Chapter
  • First Online:
Key Statistical Concepts in Clinical Trials for Pharma

Part of the book series: SpringerBriefs in Pharmaceutical Science & Drug Development ((BRIEFSPSDD))

  • 1770 Accesses

Abstract

Focus in this chapter falls on two-sided confidence intervals. A two-sided confidence interval constitutes a range of values that are defined by the lower limit and the upper limit of the interval placed around the treatment effect calculated from the trial, which is now referred to as the treatment effect point estimate. The confidence interval is a range of values that is likely to cover the true but unknown population treatment effect with a specified degree of certainty. Three commonly used levels are the 90, 95, and 99% confidence levels. This chapter explains that, when considering the information provided by confidence intervals in their review process, regulatory agencies focus on the limit that represents the ‘worst case scenario.’ For efficacy considerations, the lower limit represents the least likely benefit. For safety considerations, the upper limit represents the greatest risk.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. Rick Turner Ph.d .

Rights and permissions

Reprints and permissions

Copyright information

© 2011 The Author (s)

About this chapter

Cite this chapter

Turner, J.R. (2011). Confidence Intervals: Additional Commentary. In: Key Statistical Concepts in Clinical Trials for Pharma. SpringerBriefs in Pharmaceutical Science & Drug Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1662-3_4

Download citation

Publish with us

Policies and ethics